Perrigo : PRGO

All Perrigo Articles

63 Articles

Chris Lange | May 24, 2015 at 9:15 AM EDT

Large Companies With Fastest Revenue and Earnings Growth in 2015

S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.

Chris Lange | Apr 21, 2015 at 9:50 AM EDT

Why Teva Really Wants to Acquire Mylan

Teva Pharmaceutical Industries has just approached Mylan with a public takeover bid valued at $82 per share in cash and…

Chris Lange | Apr 10, 2015 at 1:40 PM EDT

Why Mylan Still Has Upside After Perrigo

Independent research firm Argus has weighed in on Mylan and Perrigo prior to the acquisition.

Jon C. Ogg | Apr 10, 2015 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: Apple, Citrix, Kythera, Mylan, Netflix, Weatherford and More

Friday's top analyst upgrades, downgrades and initiations include Apple, Citrix Systems, Kythera Biopharmaceuticals, Mylan, Netflix and Weatherford International.

Paul Ausick | Apr 8, 2015 at 12:25 PM EDT

Can Perrigo Get More From Mylan?

Generic drug maker Mylan has proposed to acquire rival Perrigo for $205 per share in cash and stock.

Lee Jackson | Mar 23, 2015 at 9:05 AM EDT

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks…

Chris Lange | Dec 19, 2014 at 2:58 PM EST

Merrill Lynch’s Top Health Care Stock Picks for 2015

24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.

Lee Jackson | Oct 22, 2014 at 10:05 AM EDT

3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion

A new research report from Merrill Lynch features three top pharmaceutical companies, dubbed the “Irish 3-Pack.”

Trey Thoelcke | Mar 26, 2014 at 8:45 AM EDT

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large…

Jon C. Ogg | Mar 19, 2014 at 10:10 AM EDT

Are Biotech Stocks Located in Ireland Top Buyout Candidates?

St. Patrick's Day may have come and gone for this year, but the analysts at biotech boutique shop Leerink have…

Jon C. Ogg | Feb 11, 2014 at 8:20 AM EST

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, CenturyLink, Cisco, FireEye, Infoblox, More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, February 11, 2014.…

Jon C. Ogg | Oct 21, 2013 at 8:30 AM EDT

Top Analyst Upgrades and Stocks to Buy: Apple, GE, Google, SolarCity and More

Stocks are at all-time highs again, and investors have to be wondering which stocks and sectors they should be holding,…

Jon C. Ogg | Aug 12, 2013 at 9:20 AM EDT

Merck Temodar Gets Generic Competition in Brain Cancer

ThinkstockMerck & Co. Inc. (NYSE: MRK) is seeing one more drug drive off the patent cliff. News was released on…

Jon C. Ogg | Jan 14, 2013 at 9:09 AM EST

More Flu Season Stock Winners (HITK, PTX, PRGO)

ThinkstockThe 2012 to 2013 flu season has reached what is officially at pandemic levels. The government report last week showed…

Jon C. Ogg | Nov 17, 2011 at 8:22 AM EST

Top Analyst Upgrades & Downgrades (ADSK, CCL, CHK, ENB, LEG, LULU, MU, NTAP, PRGO, QCOM, RCL, TD, TA)

These are some of Thursday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls. Autodesk Inc. (NASDAQ: ADSK)…

1 2 3 4 5

Perrigo : PRGO

All Perrigo Articles

Large Companies With Fastest Revenue and Earnings Growth in 2015

Why Teva Really Wants to Acquire Mylan

Why Mylan Still Has Upside After Perrigo

Top Analyst Upgrades and Downgrades: Apple, Citrix, Kythera, Mylan, Netflix, Weatherford and More

Can Perrigo Get More From Mylan?

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

Merrill Lynch’s Top Health Care Stock Picks for 2015

3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

Are Biotech Stocks Located in Ireland Top Buyout Candidates?

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, CenturyLink, Cisco, FireEye, Infoblox, More

Top Analyst Upgrades and Stocks to Buy: Apple, GE, Google, SolarCity and More

Merck Temodar Gets Generic Competition in Brain Cancer

More Flu Season Stock Winners (HITK, PTX, PRGO)

Top Analyst Upgrades & Downgrades (ADSK, CCL, CHK, ENB, LEG, LULU, MU, NTAP, PRGO, QCOM, RCL, TD, TA)

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Perrigo : PRGO

All Perrigo Articles

Large Companies With Fastest Revenue and Earnings Growth in 2015

Why Teva Really Wants to Acquire Mylan

Why Mylan Still Has Upside After Perrigo

Top Analyst Upgrades and Downgrades: Apple, Citrix, Kythera, Mylan, Netflix, Weatherford and More

Can Perrigo Get More From Mylan?

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

Merrill Lynch’s Top Health Care Stock Picks for 2015

3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

Are Biotech Stocks Located in Ireland Top Buyout Candidates?

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, CenturyLink, Cisco, FireEye, Infoblox, More

Top Analyst Upgrades and Stocks to Buy: Apple, GE, Google, SolarCity and More

Merck Temodar Gets Generic Competition in Brain Cancer

More Flu Season Stock Winners (HITK, PTX, PRGO)

Top Analyst Upgrades & Downgrades (ADSK, CCL, CHK, ENB, LEG, LULU, MU, NTAP, PRGO, QCOM, RCL, TD, TA)

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Featured Reads

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk